Open AccessConsiderations for use of direct oral anticoagulants in arterial disease
Author(s) -
Siegal Deborah M.,
Anand Sonia S.
Publication year - 2021
Publication title -
research and practice in thrombosis and haemostasis
Language(s) - English
Resource type - Journals
ISSN - 2475-0379
DOI - 10.1002/rth2.12502
Subject(s) - medicine , stroke (engine) , arterial disease , cardiology , disease , randomized controlled trial , intensive care medicine , peripheral , clinical trial , vascular disease , coronary heart disease , mechanical engineering , engineering
Cardiovascular diseases including coronary heart disease, stroke, and peripheral arterial disease were responsible for an estimated 18 million deaths in 2017. Despite advances in management over the past several decades, these patients continue to have substantial risk of subsequent cardiovascular events. We provide a narrative review of randomized clinical trials evaluating direct oral anticoagulants (DOACs) for the treatment of acute coronary syndromes, noncardioembolic ischemic stroke, embolic stroke of undetermined source, and peripheral arterial disease. In these conditions, considerations for use of single antiplatelet therapy, dual antiplatelet therapy, or low‐dose DOACs used together with antiplatelet therapy are presented.